ACELYRIN, Inc. Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Acelyrin, Inc. |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
TL;DR
ACELYRIN filed its Q1 2025 10-Q. Financials updated.
AI Summary
ACELYRIN, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational activities during the first quarter of 2025. Key financial data and disclosures relevant to investors are presented.
Why It Matters
This filing provides investors with an update on ACELYRIN's financial health and operational performance for the first quarter of 2025, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, ACELYRIN faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- ACELYRIN, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Filing date
- 4149 LIBERTY CANYON RD. (address) — Company's business and mailing address
- AGOURA HILLS, CA (location) — City and State of company's address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 14, 2025.
What is ACELYRIN, Inc.'s primary industry classification?
ACELYRIN, Inc.'s primary industry classification is Pharmaceutical Preparations [2834].
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Where is ACELYRIN, Inc. located?
ACELYRIN, Inc. is located at 4149 Liberty Canyon Rd., Agoura Hills, CA 91301.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding ACELYRIN, Inc..